Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril

F. Simko, O. Pechanova, K. Repova, S. Aziriova, K. Krajcirovicova, P. Celec, L. Tothova, S. Vrankova, L. Balazova, S. Zorad, M. Adamcova,

. 2017 ; 18 (8) : . [pub] 20170725

Jazyk angličtina Země Švýcarsko

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024781

Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. In addition, the lactacystin-model was compared with NG-nitro-l-arginine-methyl ester (L-NAME)- and continuous light-induced hypertension. Six groups of three-month-old male Wistar rats (11 per group) were treated for six weeks as follows: control (vehicle), L-NAME (40 mg/kg/day), continuous light (24 h/day), lactacystin (5 mg/kg/day) alone, and lactacystin with captopril (100 mg/kg/day), or melatonin (10 mg/kg/day). Lactacystin treatment increased systolic blood pressure (SBP) and induced fibrosis of the left ventricle (LV), as observed in L-NAME-hypertension and continuous light-hypertension. LV weight and the cross-sectional area of the aorta were increased only in L-NAME-induced hypertension. The level of oxidative load was preserved or reduced in all three models of hypertension. Nitric oxide synthase (NOS) activity in the LV and kidney was unchanged in the lactacystin group. Nuclear factor-kappa B (NF-κB) protein expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024781
003      
CZ-PrNML
005      
20231121102408.0
007      
ta
008      
180709s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms18081612 $2 doi
035    __
$a (PubMed)28757582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. 3rd Clinic of Internal Medicine, Faculty of Medicine, Comenius University, 83305 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. fedor.simko@fmed.uniba.sk.
245    10
$a Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril / $c F. Simko, O. Pechanova, K. Repova, S. Aziriova, K. Krajcirovicova, P. Celec, L. Tothova, S. Vrankova, L. Balazova, S. Zorad, M. Adamcova,
520    9_
$a Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. In addition, the lactacystin-model was compared with NG-nitro-l-arginine-methyl ester (L-NAME)- and continuous light-induced hypertension. Six groups of three-month-old male Wistar rats (11 per group) were treated for six weeks as follows: control (vehicle), L-NAME (40 mg/kg/day), continuous light (24 h/day), lactacystin (5 mg/kg/day) alone, and lactacystin with captopril (100 mg/kg/day), or melatonin (10 mg/kg/day). Lactacystin treatment increased systolic blood pressure (SBP) and induced fibrosis of the left ventricle (LV), as observed in L-NAME-hypertension and continuous light-hypertension. LV weight and the cross-sectional area of the aorta were increased only in L-NAME-induced hypertension. The level of oxidative load was preserved or reduced in all three models of hypertension. Nitric oxide synthase (NOS) activity in the LV and kidney was unchanged in the lactacystin group. Nuclear factor-kappa B (NF-κB) protein expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.
650    _2
$a acetylcystein $x škodlivé účinky $x analogy a deriváty $7 D000111
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x aplikace a dávkování $x farmakologie $7 D000959
650    _2
$a kaptopril $x aplikace a dávkování $x farmakologie $7 D002216
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a fibróza $7 D005355
650    _2
$a srdeční komory $x účinky léků $x patologie $7 D006352
650    _2
$a hypertenze $x chemicky indukované $x farmakoterapie $x etiologie $7 D006973
650    _2
$a světlo $x škodlivé účinky $7 D008027
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melatonin $x aplikace a dávkování $x farmakologie $7 D008550
650    _2
$a NG-nitroargininmethylester $x škodlivé účinky $7 D019331
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a remodelace komor $x účinky léků $7 D020257
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pechanova, Olga $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 81371 Bratislava, Slovakia. olga.pechanova@savba.sk.
700    1_
$a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. repova.k@gmail.com.
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. silvia.aziriova@gmail.com.
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. krikratina@gmail.com.
700    1_
$a Celec, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 81108 Bratislava, Slovakia. petercelec@gmail.com. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia. petercelec@gmail.com.
700    1_
$a Tothova, Lubomira $u Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia. tothova.lubomira@gmail.com.
700    1_
$a Vrankova, Stanislava $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 81371 Bratislava, Slovakia. stanislava.vrankova@savba.sk.
700    1_
$a Balazova, Lucia $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. balazova.luc@gmail.com.
700    1_
$a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia. Stefan.Zorad@savba.sk. $7 xx0310348
700    1_
$a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine, Charles University, 50003 Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 18, č. 8 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28757582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20231121102405 $b ABA008
999    __
$a ok $b bmc $g 1316912 $s 1021702
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 18 $c 8 $e 20170725 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...